Details

Autor(en) / Beteiligte

• MASOUDI, Amirhadi
• ELOPRE, Marily
• AMINI, Elham
• NAGEL, Margaret E
• ATER, Joann L
• GOPALAKRISHNAN, Vidya
• WOLFF, Johannes E. A

Titel

Influence of Valproic Acid on Outcome of High-grade Gliomas in Children

Ist Teil von

• Anticancer research, 2008-07, Vol.28 (4C), p.2437-2442

Ort / Verlag

Attiki: International Institute of Anticancer Research

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• Background: Chemotherapy has limited effects in the treatment of high-grade gliomas (HGGs). Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, may sensitize HGGs to radiochemotherapy. As the drug has been given frequently as an antiepileptic drug, a retrospective analysis was conducted to ensure relevant information was not missed before a prospective study was launched. Materials and Methods: An analysis of 66 pediatric patients (range, 1-19 years of age) with glioblastoma multiforme (GBM) (n=40) or anaplastic astrocytoma (AA) (n=26) was retrospectively conducted for predictors of survival and response and for effects of VPA on outcome or toxicity. Results: The overall survival (OS) was better for AA (p=0.0114) and complete resection (p<0.00005) and event-free survival (EFS) was better for complete resection (p=0.0049). Nine patients received VPA (for seizure) plus further oncological treatment. The most severe adverse effect was a pulmonary embolism (n=1); no other severe side-effects were noted. The response to nonsurgical treatment after 8 weeks was: complete response (CR): 0, partial response (PR): 3, stable disease (SD): 4, progressive disease (PD): 2. Some of the patients with SD responded later resulting in best response: CR:0, PR:5, SD:2, PD:2. Conclusion: Treatment with VPA plus radiochemotherapy is well tolerated with an encouraging response rate.